With Compounded GLP-1s Ending, Now What?

The phasing out of compounded GLP-1 medications has left many patients uncertain about how to move forward in managing obesity. In this episode of Fresh Perspectives, OAC President and CEO Joe Nadglowski sits down with Dr. Angela Fitch, MD, FACP, FOMA, a board-certified obesity medicine physician, to discuss why compounded GLP-1s are no longer available, the safe and effective alternatives patients can consider, and how they can successfully navigate this transition with the support of their healthcare providers.